News & Updates

Product Highlight - Bacillus clausii (Probicosta)

Powder for oral use 2 billion CFU

Product Highlight - Paracetamol + Phenylephrine HCl + Dextromethorphan HBr (Nasatapp Cough)

Capsule 325 mg/25 mg/10 mg

Product Highlight - Fluticasone furoate, umeclidinium Br, vilanterol trifenatate (Trelegy Ellipta)

Dry powder for inhalation 100 mcg/62.5 mcg/25 mcg

Product Highlight - Multivitamins + Iron (Appetite OB)

Capsule

Product Highlight - Paracetamol + Orphenadrine citrate (Norpriexia/Norpriexia Forte)

FC tab (Forte) 650 mg/35 mg

Diabetes Mellitus Type II DMT2 Vildagliptin

Pharmacists, your partners in self-care

September 25 marks the World Pharmacists Day, with this year’s theme, “Pharmacists: Meeting Global Health Needs.” The day holds importance as the world recognizes and celebrates the role of pharmacists in building healthy communities.

Pharmacists are integral to healthcare. They are at the forefront of self-care and are often the first point of contact for people seeking health advice in the community. This article focuses on the evolving role of pharmacists in oral health care, skin care, and smoking cessation.

3-in-1 combo test supports differential diagnosis of COVID-19 and Flu A&B for timely treatment

Rapid antigen tests have become valuable for identifying active COVID-19 infections and facilitating effective control measures. However, with the concurrent upswing in COVID and flu (influenza) cases, clinicians need a test that simultaneously detects COVID-19 and flu to support timely and accurate diagnosis and treatment.

Targeting PV source with ropeginterferon alfa-2b revolutionizes treatment

Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by overproduction of red blood cells, which poses a significant risk of thrombohaemorrhagic complications and impaired survival. Traditionally, treatment approaches have focused on managing the symptoms and reducing haematocrit levels, but these do not address the underlying cause of the disease.

Ropeginterferon alfa-2b (BESREMi, PharmaEssentia), an innovative monopegylated long-acting interferon, offers a novel approach by directly targeting and depleting JAK2-mutated hematopoietic stem cells (HSCs) in the bone marrow, which is the source of the disease. This article focuses on the role of ropeginterferon alfa-2b in transforming the treatment landscape for PV, its mechanisms, clinical benefits, and potential to significantly improve patient outcomes.

COVID-19 hospitalizations remain deadlier than flu in 2023-2024

A study compared mortality rates from COVID-19 and influenza hospitalizations during fall-winter 2023-2024.¹